← All Onkure Therapeutics, INC filings

Onkure Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
OKUR
Onkure Therapeutics, INC
10-K: OnKure Therapeutics Faces Going Concern Doubt Amid Promising Cancer Drug Trials
OnKure Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses and a going concern warning, despite advancing its lead cancer drug candidate, OKI-219, through Phase 1 trials with favorable preliminary safety data.
NASDAQ
OKUR
Onkure Therapeutics, INC
10-K: OnKure Therapeutics (OKUR) Files 10-K Annual Report for Fiscal Year 2024
OnKure Therapeutics reports its 2024 financial results and provides an update on its clinical development programs, including OKI-219.
NASDAQ
OKUR
Onkure Therapeutics, INC
10-K/A: Reneo Pharmaceuticals Files Amended 10-K to Include Omitted Information
Reneo Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include information previously omitted regarding directors, executive officers, and corporate governance.
NASDAQ
OKUR
Onkure Therapeutics, INC
10-K: Reneo Pharmaceuticals 10-K Filing: Strategic Review Underway After Trial Setback
Reneo Pharmaceuticals suspends development of mavodelpar after a failed clinical trial and initiates a strategic review process to maximize stockholder value.